Alliance Pharma (LON:APH) Rating Reiterated by Numis Securities

Alliance Pharma (LON:APH – Get Rating)‘s stock had its “buy” rating reaffirmed by equities research analysts at Numis Securities in a research note issued on Thursday, Marketbeat.com reports. They currently have a GBX 105 ($1.31) price objective on the stock. Numis Securities’ price objective suggests a potential upside of 70.73% from the company’s current price.

Other research analysts have also issued research reports about the stock. Peel Hunt initiated coverage on shares of Alliance Pharma in a research note on Friday, March 17th. They set a “hold” rating and a GBX 65 ($0.81) target price for the company. Berenberg Bank reissued a “buy” rating and set a GBX 105 ($1.31) target price on shares of Alliance Pharma in a research report on Thursday.

Alliance Pharma Stock Down 1.3 %

Shares of APH opened at GBX 61.50 ($0.76) on Thursday. The company has a quick ratio of 1.42, a current ratio of 2.24 and a debt-to-equity ratio of 47.83. The stock has a fifty day simple moving average of GBX 64.51 and a two-hundred day simple moving average of GBX 60.68. Alliance Pharma has a 52-week low of GBX 34.14 ($0.42) and a 52-week high of GBX 120 ($1.49). The company has a market capitalization of £332.12 million, a PE ratio of 3,450.00, a price-to-earnings-growth ratio of 1.04 and a beta of 0.54.

About Alliance Pharma

(Get Rating)

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products.